Halyard Ventures

Halyard is a biotechnology company founded by Flagship Pioneering that focuses on developing a new class of medicines targeting the glycocalyx, the sugar-rich layer coating the surface of all human cells. The company's platform is designed to precisely remodel the glycocalyx to restore cellular homeostasis and treat diseases where this layer is compromised, such as inflammatory and fibrotic conditions. By leveraging deep expertise in glycobiology and protein engineering, Halyard aims to address the "sugar code" of disease, a frontier that has been historically challenging for drug discovery. The company is currently advancing a pipeline of pre-clinical programs focused on high-need indications in immunology and organ-specific fibrosis. Led by industry veterans, Halyard represents a novel approach to therapeutic intervention at the cellular interface.